Sigilon Therapeutics to Present at Upcoming September Conferences
CAMBRIDGE, Mass., Sept. 7, 2017 /PRNewswire/ -- Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced the company will present at the following conferences in September.
24th Annual BioCentury NewsMakers in the Biotech Industry Conference
| Presenter: |
Devyn Smith, Ph.D., Sigilon Therapeutics Chief Strategy Officer and Head of Operations |
| Date: |
Friday, Sept. 8, 2017 |
| Time: |
11 a.m. EDT |
| Location: |
Millennium Broadway Hotel, New York |
GTCbio 4th Cell & Gene Therapy (CGT) Conference
| Title: |
Next Generation Cell Therapies – Will These Revolutionize Healthcare? |
| Presenter: |
Devyn Smith, Ph.D., Sigilon Therapeutics Chief Strategy Officer and Head of Operations |
| Date: |
Monday, Sept. 11, 2017 |
| Time: |
11:10 a.m. EDT |
| Location: |
Hyatt Regency Boston |
15th Annual International Nanomedicine & Drug Delivery Symposium
| Title: |
Immune Modulatory Biomaterials for Cell-Based Therapies |
| Presenter: |
Omid Veiseh, Ph.D., Sigilon Therapeutics Co-Founder |
| Date: |
Saturday, Sept. 23, 2017 |
| Time: |
3 p.m. EDT |
| Location: |
BSRB Kahn Auditorium, University of Michigan, Ann Arbor, Michigan |
About Sigilon Therapeutics
Sigilon Therapeutics is developing treatments for chronic diseases using new biomaterials developed at the Massachusetts Institute of Technology that can shield implanted cells from immune attack. Treatments based on Sigilon Therapeutics' technology platform include cell implants that act as "protein factories" and responsive "living therapeutics," providing more natural control for diseases that are currently treated with intermittent injection or infusion. Initial areas of focus include hematologic, enzyme deficiency, endocrine and metabolic disorders. More natural control would restore health and free patients from the need for therapies that are disruptive to quality of life.
For more information please visit www.sigilon.com or follow us on Twitter at https://twitter.com/Sigilon_Inc.
SOURCE Sigilon Therapeutics
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article